Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 48

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q86UV5

UPID:
UBP48_HUMAN

ALTERNATIVE NAMES:
Deubiquitinating enzyme 48; Ubiquitin thioesterase 48; Ubiquitin-specific peptidase 48; Ubiquitin-specific protease 48; Ubiquitin-specific-processing protease 48

ALTERNATIVE UPACC:
Q86UV5; B7ZKS7; Q2M3I4; Q5SZI4; Q5T3T5; Q6NX53; Q8N3F6; Q96F64; Q96IQ3; Q9H5N3; Q9H5T7; Q9NUJ6; Q9NXR0

BACKGROUND:
The enzyme Ubiquitin carboxyl-terminal hydrolase 48, also referred to as Ubiquitin-specific-processing protease 48, is integral to the ubiquitin-proteasome system. It facilitates the removal of ubiquitin from ubiquitinated proteins, a key step in protein catabolism. Its interaction with RELA and TRAF2 underscores its regulatory function in NF-kappa-B signaling, a pathway critical for immune and inflammatory responses.

THERAPEUTIC SIGNIFICANCE:
Given its association with Deafness, autosomal dominant, 85, characterized by early-onset progressive hearing loss, the study of Ubiquitin carboxyl-terminal hydrolase 48 holds promise for developing novel therapeutic approaches. Understanding the role of this protein could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.